Sheila H Ridner1, Mary S Dietrich. 1. Vanderbilt University School of Nursing, 461 21st Avenue South, Godchaux Hall, Nashville, TN, 37240, USA, sheila.ridner@vanderbilt.edu.
Abstract
PURPOSE: The purpose of this instrument development project was to create a self-report tool to evaluate arm lymphedema and associated symptoms in breast cancer survivors. METHODS: The Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A) was developed and tested in three phases: phase 1-literature review and expert panel; phase 2-preliminary validation; and phase 3-final validation. RESULTS: Phase 1: The most common symptoms experienced by breast cancer survivors with lymphedema were identified. A 52-item scale was developed. Phase 2: 128 community-dwelling breast cancer survivors (64 with lymphedema, 64 without lymphedema) completed the LSIDS-A. Feedback from the participants was that the format was "clear" and "made sense"; therefore, the response structure was left intact. Sixteen items were deleted leaving a 36-item revised instrument. Phase 3: Subsequent testing in a total sample of 236 breast cancer survivors with lymphedema was undertaken. The Cronbach's alpha reliability values for the overall intensity and distress scores were 0.93 and 0.94, respectively. The Kuder-Richardson values ranged from 0.66 to 0.92. Divergent validity evaluated against Marlowe-Crowne Social Desirebility Scale overall was acceptable (intensity, r s = 0.08; distress, r s = -0.12). Convergent validity was acceptable as tested with multiple instruments (e.g., Functional Assessment of Cancer Therapy-Breast +4, overall intensity r s = -0.44, overall distress r s = -.48) CONCLUSIONS: The 30-item LSIDS-A is a valid and reliable instrument that can be used to assess arm lymphedema and its associated symptoms.
PURPOSE: The purpose of this instrument development project was to create a self-report tool to evaluate arm lymphedema and associated symptoms in breast cancer survivors. METHODS: The Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A) was developed and tested in three phases: phase 1-literature review and expert panel; phase 2-preliminary validation; and phase 3-final validation. RESULTS: Phase 1: The most common symptoms experienced by breast cancer survivors with lymphedema were identified. A 52-item scale was developed. Phase 2: 128 community-dwelling breast cancer survivors (64 with lymphedema, 64 without lymphedema) completed the LSIDS-A. Feedback from the participants was that the format was "clear" and "made sense"; therefore, the response structure was left intact. Sixteen items were deleted leaving a 36-item revised instrument. Phase 3: Subsequent testing in a total sample of 236 breast cancer survivors with lymphedema was undertaken. The Cronbach's alpha reliability values for the overall intensity and distress scores were 0.93 and 0.94, respectively. The Kuder-Richardson values ranged from 0.66 to 0.92. Divergent validity evaluated against Marlowe-Crowne Social Desirebility Scale overall was acceptable (intensity, r s = 0.08; distress, r s = -0.12). Convergent validity was acceptable as tested with multiple instruments (e.g., Functional Assessment of Cancer Therapy-Breast +4, overall intensity r s = -0.44, overall distress r s = -.48) CONCLUSIONS: The 30-item LSIDS-A is a valid and reliable instrument that can be used to assess arm lymphedema and its associated symptoms.
Authors: Sheila H Ridner; Mei R Fu; Ausanee Wanchai; Bob R Stewart; Jane M Armer; Janice N Cormier Journal: Nurs Res Date: 2012 Jul-Aug Impact factor: 2.381
Authors: Sheila H Ridner; Barbara Murphy; Jie Deng; Nancy Kidd; Emily Galford; Candace Bonner; Stewart M Bond; Mary S Dietrich Journal: Breast Cancer Res Treat Date: 2011-09-30 Impact factor: 4.872
Authors: Jennifer K Doersam; Mary S Dietrich; Melissa A Adair; Bethany Rhoten; Jie Deng; Sheila H Ridner Journal: Lymphat Res Biol Date: 2019-08-05 Impact factor: 2.589
Authors: Louise Marie Beelen; Anne-Margreet van Dishoeck; Elena Tsangaris; Michelle Coriddi; Joseph H Dayan; Andrea L Pusic; Anne Klassen; Dalibor Vasilic Journal: Ann Surg Oncol Date: 2020-11-28 Impact factor: 5.344
Authors: Sheila H Ridner; Chirag Shah; John Boyages; Louise Koelmeyer; Nicolas Ajkay; Sarah M DeSnyder; Sarah A McLaughlin; Mary S Dietrich Journal: Cancer Med Date: 2020-06-01 Impact factor: 4.452
Authors: Louise A Koelmeyer; Emma Moloney; John Boyages; Kerry A Sherman; Catherine M Dean Journal: Breast Cancer Res Treat Date: 2020-10-01 Impact factor: 4.872
Authors: Sheila H Ridner; Mary S Dietrich; Jie Deng; Sandra L Ettema; Barbara Murphy Journal: Support Care Cancer Date: 2020-06-02 Impact factor: 3.603